Peter Verhamme
Peter Verhamme
Center for Molecular and Vascular Biology - University of Leuven
Verified email at uzleuven.be - Homepage
TitleCited byYear
Oral rivaroxaban for symptomatic venous thromboembolism
Einstein Investigators
New England Journal of Medicine 363 (26), 2499-2510, 2010
25842010
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism
Einstein–PE Investigators
New England Journal of Medicine 366 (14), 1287-1297, 2012
18932012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism
Einstein–PE Investigators
New England Journal of Medicine 366 (14), 1287-1297, 2012
18832012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism
EPE Investigators
N Engl j Med 2012 (366), 1287-1297, 2012
1880*2012
Idarucizumab for dabigatran reversal
CV Pollack Jr, PA Reilly, J Eikelboom, S Glund, P Verhamme, ...
New England Journal of Medicine 373 (6), 511-520, 2015
14282015
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism
Hokusai-VTE Investigators
New England journal of medicine 369 (15), 1406-1415, 2013
13162013
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation
H Heidbuchel, P Verhamme, M Alings, M Antz, HC Diener, W Hacke, ...
Ep Europace 17 (10), 1467-1507, 2015
10492015
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation
H Heidbuchel, P Verhamme, M Alings, M Antz, W Hacke, J Oldgren, ...
Europace 15 (5), 625-651, 2013
9682013
Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease
P Holvoet, A Mertens, P Verhamme, K Bogaerts, G Beyens, R Verhaeghe, ...
Arteriosclerosis, thrombosis, and vascular biology 21 (5), 844-848, 2001
5822001
Andexanet alfa for acute major bleeding associated with factor Xa inhibitors
SJ Connolly, TJ Milling Jr, JW Eikelboom, CM Gibson, JT Curnutte, A Gold, ...
New England Journal of Medicine 375 (12), 1131-1141, 2016
5222016
Rivaroxaban with or without aspirin in stable cardiovascular disease
JW Eikelboom, SJ Connolly, J Bosch, GR Dagenais, RG Hart, ...
New England Journal of Medicine 377 (14), 1319-1330, 2017
5122017
Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial
D Aujesky, PM Roy, F Verschuren, M Righini, J Osterwalder, M Egloff, ...
The Lancet 378 (9785), 41-48, 2011
4482011
EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary
H Heidbuchel, P Verhamme, M Alings, M Antz, W Hacke, J Oldgren, ...
European heart journal 34 (27), 2094-2106, 2013
4092013
Idarucizumab for dabigatran reversal—full cohort analysis
CV Pollack Jr, PA Reilly, J Van Ryn, JW Eikelboom, S Glund, ...
New England Journal of Medicine 377 (5), 431-441, 2017
3572017
Edoxaban for the treatment of cancer-associated venous thromboembolism
GE Raskob, N van Es, P Verhamme, M Carrier, M Di Nisio, D Garcia, ...
New England Journal of Medicine 378 (7), 615-624, 2018
3282018
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
J Steffel, P Verhamme, TS Potpara, P Albaladejo, M Antz, L Desteghe, ...
European heart journal 39 (16), 1330-1393, 2018
3122018
Rivaroxaban or aspirin for extended treatment of venous thromboembolism
JI Weitz, AWA Lensing, MH Prins, R Bauersachs, J Beyer-Westendorf, ...
New England Journal of Medicine 376 (13), 1211-1222, 2017
2722017
Factor XI antisense oligonucleotide for prevention of venous thrombosis
HR Büller, C Bethune, S Bhanot, D Gailani, BP Monia, GE Raskob, ...
New England Journal of Medicine 372 (3), 232-240, 2015
2642015
Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the Health, Aging, and Body Composition study
P Holvoet, TB Harris, RP Tracy, P Verhamme, AB Newman, SM Rubin, ...
Arteriosclerosis, thrombosis, and vascular biology 23 (8), 1444-1448, 2003
1852003
Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in …
A Mertens, P Verhamme, JK Bielicki, MC Phillips, R Quarck, W Verreth, ...
Circulation 107 (12), 1640-1646, 2003
1842003
The system can't perform the operation now. Try again later.
Articles 1–20